Clinical Trials on Neuro-Oncology
early LITT
|
Title in German |
Studie zur Lasertherapie vor der Strahlenbehandlung bei erneutem Glioblastom-Wachstum |
|
Title in English |
Laser Intersitial Thermal Therapy for Ultra-Early, Pre-Radiotherapy Glioblastoma Recurrence |
|
Description |
Bei rund 40 % der Patientinnen und Patienten mit einem Glioblastom zeigt sich bereits in der Planungs-MRI vor Beginn der Strahlentherapie ein sehr frühes erneutes Tumorwachstum. Für diese besonders frühe Form des Rückfalls gibt es bisher keine gezielte Behandlung. Die LITT-Studie untersucht, ob eine minimal-invasive Laserbehandlung in dieser Situation sinnvoll eingesetzt werden kann, sich die Laserbehandlung sicher und ohne Verzögerung der Standardtherapie in den Behandlungsablauf integrieren lässt und ob sie möglicherweise die Wirkung der anschliessenden Strahlen- und Chemotherapie verbessern kann. |
|
Phase |
|
|
Head Clinical Trial |
|
|
Study-Coordinator |
|
|
Back-up |
|
|
Status |
recruiting |
|
BASEC number |
2025-01709 |
|
Kofam number |
|
|
WHO registry number |
|
|
Insel number |
6232 |
ETOP 19-21 USZ-STRIKE
|
Title in German |
ETOP 19-21 USZ-STRIKE |
|
Title in English |
ETOP 19-21 USZ-STRIKE |
|
Description |
Immunotherapy or targeted therapy with or without stereotactic radiosurgery in patients with brain metastases from melanoma or non-small cell lung cancer. |
|
Phase |
III |
|
Head Clinical Trial |
|
|
Study Coordinator |
|
|
Back-up |
|
|
Status |
aktive |
|
BASEC-Nummer |
2022-01064 |
|
Nummer aus Studienregister (z.B. clinicaltrials.gov) |
NCT05522660 |
|
WHO-Register-Nummer |
|
|
Insel-Nummer |
5406 |
MENTOR
|
Title in German |
Magnetstimulation zur Planung von Radiochirurgischen Eingriffen – Eine Pilotstudie |
|
Title in English |
Motor Eloquent Navigated Transcranial magnetic stimulation for Radiosurgery planning - A proof of concept study |
|
Description |
Die Strahlentherapie ist ein wichtiger Bestandteil der Behandlung von Hirnmetastasen. Eine besondere Herausforderung besteht darin, Tumorzellen wirksam zu bestrahlen und gleichzeitig für die Bewegung wichtige Hirnareale zu schonen, um bleibende Einschränkungen zu vermeiden. Die bisherige Bestrahlungsplanung basiert vor allem auf anatomischen Bilddaten, die funktionell relevante Bewegungszentren nicht immer zuverlässig darstellen, insbesondere nach einer Operation. Mithilfe der navigierten transkraniellen Magnetstimulation (nTMS), einem nicht-invasiven Verfahren zur funktionellen Kartierung des Gehirns, können individuelle Bewegungsareale präzise identifiziert und zusätzliche funktionelle Informationen in die Bestrahlungsplanung integriert werden. Die Studie untersucht, ob dadurch bewegungsrelevante Hirnregionen besser geschont werden können, ohne die Wirksamkeit der Tumorbehandlung zu beeinträchtigen, und ob dies zu besseren funktionellen Ergebnissen sowie weniger Nebenwirkungen führt. |
|
Phase |
Pilotstudie |
|
Head Clinical Trial |
|
|
Study-Nurse |
|
|
Back-up |
|
|
Status |
active since 16.04.2026 |
|
BASEC number |
2026-00163 |
|
Study registry number (e.g. clinicaltrials.gov) |
NCT07415668 |
|
Insel number |
STD0007701 |
PREOP-2
|
Title in German |
Eine multizentrische prospektive, interventionelle, randomisierte Studie zur präoperativen Radiochirurgie im Vergleich zur postoperativen stereotaktischen Strahlentherapie bei resektablen Hirnmetastasen. |
|
Title in English |
A multicentre prospective, interventional, randomised trial of preoperative radiosurgery compared with postoperative stereotactic radiotherapy for resectable brain metastases. |
|
Description |
For brain metastases (offshoots of cancer in the brain) when they reach a certain size, different treatments are used. Currently, at the Inselspital Bern, the metastasis is first operated on and then (post-operatively) the region in which the metastasis was located (so-called “tumor bed”) is irradiated for 5 days. In some other clinics the opposite approach is also carried out, i.e. a single radiation treatment is carried out before the operation (so-called pre-operative). In our research project, we want to find out whether the return of metastases (recurrences) from the tumor bed is equally common in both forms of treatment and how patients experience the therapies (quality of life). |
|
Phase/Biobank/etc. |
III |
|
Head Clinical Trial |
|
|
Study-Nurse |
|
|
Back-up |
|
|
Status |
active since 02.06.2022 |
|
BASEC-Nummer |
2021-02094 |
|
Nummer aus Studienregister |
Clinicaltrials.gov: NCT 05124236 |
|
Insel-Nummer |
5139 |
Resdex-Studie
|
Title in German |
Studie zur Implementierung eines restriktiven Dexamethason Behandlungsregimes in Hirntumor-Patienten |
|
Title in English |
Restrictive Use of Dexamethasone in Glioblastoma |
|
Description |
Ziel der Studie ist es zu untersuchen, ob die neurochirurgische Behandlung von Hirntumoren bei bestimmten Patienten ohne zusätzliche Verabreichung von Dexamethason (Kortison) oder nur einem Minimum (Dexamethason) durchgeführt werden kann. |
|
Phase/Biobank/etc. |
Phase II |
|
Head Clinical Trial |
|
|
Study-Nurse |
|
|
Back-up |
|
|
Status |
active since 08.05.2020 |
|
BASEC-Nummer |
2020-00286 |
|
KOFAM |
|
|
WHO-Register-Nummer |
NCT04266977 |
|
Insel-Nummer |
4381 |
RESURGE
|
Title in German |
RESURGE – Randomisierte kontrollierte komparative Phase-II-Studie zur Chirurgie bei Glioblastom Rezidiv. |
|
Title in English |
RESURGE – Randomized Controlled Comparative Phase II Trial on Surgery for Glioblastoma Recurrence |
|
Description |
To date, there are two established strategies to treat a recurrent brain tumor: |
|
- Reoperation for the brain tumor, followed by second-line therapy (chemotherapy or radiotherapy) |
|
|
- Immediate second-line therapy (chemotherapy or radiotherapy) without prior surgery. It is still unclear which of the two treatment strategies is more successful. The aim of this study is to investigate which of the two treatment strategies is more successful. |
|
|
It is still unclear which of the two treatment strategies is more successful. The aim of this study is to investigate which of the two treatment strategies is more successful. |
|
|
Phase/Biobank/etc. |
Phase II |
|
Head Clinical Trial |
|
|
Study-Nurse |
|
|
Back-up |
|
|
Status |
active since 2015 |
|
BASEC-Nummer |
2016-1462 |
|
KOFAM |
|
|
WHO-Register-Nummer |
NCT02394626 |
|
Insel-Nummer |
2752 |
Sonobird
|
Title in German |
SonoCloud-9 in Kombination mit Carboplatin im Vergleich zu standardmässigen Chemotherapien (Lomustin oder Temozolomid) beim wiederaufgetretenen Glioblastom (GBM) - (SONOBIRD) |
|
Title in English |
A randomized, open-label, multicentric, two-arm pivotal trial of SonoCloud-9 combined with carboplatin (CBDCA) vs standard of care lomustine (CCNU) or temozolomide (TMZ) in patients undergoing planned resection for first recurrence glioblastoma |
|
Description |
The standard treatment for a recurrent brain tumor usually consists of surgery and chemotherapy. The aim is to inhibit tumor growth. In this study, we are investigating the success of a treatment that is a combination of carboplatin (chemotherapy) and the SC9 implantable device. We want to find out how effective and safe this procedure is compared to standard therapy. |
|
Phase/Biobank/etc. |
Phase III |
|
Head Clinical Trial |
|
|
Study Coordinator |
|
|
Study Nurse |
|
|
Sub-Investigator Med. Onk. |
|
|
Back-up |
|
|
Status |
temp. closed |
|
BASEC-Nummer |
2023-D00119 |
|
KOFAM |
|
|
WHO-Register-Nummer |
NCT05902169 |
|
Insel-Nummer |
5757 |
SwissNOS GluGlio
|
Title in German |
Glutamat Signalhemmer für neu diagnostiziertes Glioblastom: eine randomisierte, offene, multizentrische Phase IB/II Studie |
|
Title in English |
A phase Ib/II randomized, open label drug repurposing trial of glutamate signaling inhibitors in combination with chemoradiotherapy in patients with newly diagnosed glioblastoma (GLUGLIO) |
|
Phase/Biobank/ect. |
Ib/II |
|
Description |
The study examines the effectiveness of a combination of the study drugs gabapentin, sulfasalazine and memantine together with standard therapy (radiotherapy and chemotherapy with temozolomide). All three study drugs inhibit the glutamate signaling pathway at different points. Glutamate is a messenger substance found in the human brain that is released by both glioblastoma cells and brain cells. Glutamate promotes the growth and invasion of glioblastoma cells into healthy brain tissue. This is intended to be prevented by additional administration of the three study drugs. |
|
Head Clinical Trial |
|
|
Study-Nurse |
|
|
Status |
open for patient recruitment: 01.05.2023 |
|
BASEC Nummer |
BASEC2022-01877 |
|
KOFAM |
SNCTP000005305 |
|
EudraCT No. |
NCT05664464 |
|
Insel-Nummer |
5419 |
TRANSEKT
|
Title in German |
Vergleich zweier Stimulationsmethoden zur Messung der Bewegungspotenziale während der operativen Entfernung von Hirntumoren im Hinblick auf die Prognosegenauigkeit von Lähmungen nach der Operation (TRANSEKT-Studie) |
|
Title in English |
Comparison between transcranial and direct cortical stimulation of motor evoked potentials during the resection of supratentorial brain tumors in terms of prognostic accuracy for postoperative motor deficits: A multicenter parallel-group randomized study |
|
Description |
When operating on tumors within the skull, which are located in an area of the brain that, among other things, controls the movement of certain parts of the body (hand, arm, leg or foot), it is necessary to monitor the movement functions during the operation in order to expand the tumor as much as possible remove without impairing the movement function. |
|
The aim of this study is to compare two methods of monitoring movement functions: transcranial stimulation and direct cortical stimulation. Transcranial stimulation is carried out using electrodes that are fixed at specific points on the scalp. The direct cortical stimulation is carried out using strip electrodes, which are pushed under the meninges after the skull has been opened and come to rest directly on the surface of the brain. |
|
|
Phase |
II |
|
Head Clinical Trial |
PD Dr. med. Tammam Abboud (Bern: Prof. Dr. med. Kathleen Seidel) |
|
Study Coordinator |
|
|
Back-up |
|
|
Status |
active since 14.07.2022 |
|
BASEC-Nummer |
2021-D0056 |
|
Nummer aus Studienregister (z.B. clinicaltrials.gov) |
DRKS00023256 |
|
WHO-Register-Nummer |
|
|
Insel-Nummer |
5141 |